YmAbs Therapeutics (YMAB)
(Real Time Quote from BATS)
$16.30 USD
-0.20 (-1.21%)
Updated Mar 28, 2024 11:40 AM ET
2-Buy of 5 2
D Value C Growth C Momentum D VGM
Brokerage Reports
Y-mAbs Therapeutics, Inc. [YMAB]
Reports for Purchase
Showing records 1 - 20 ( 145 total )
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Factoring in Revenue from SADA Assets; Raising PT to $21
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for YMAB 112223
Provider: Stock Traders Daily
Analyst: Research Department
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Y-mAbs Looking for SADA to Make a Happy New Year
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
New CEO Appointed; CD38-SADA Cleared to Enter Clinic; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Pulling a U-Turn on YMAB; Upgrading to OUTPERFORM
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Restructuring Due to Program De-Prioritization; Lowering PT to $11
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Chinese Office of Cybersecurity Review Investigating Micron
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D